[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"copd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:copd":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,205,0,25,[9,51,80,104,132,157,185,212,234,260,283,296,322,342,372,395,433,456,480,509,536,555,574,599,628],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100054136","phase-3-long-term-safety-and-tolerability-of-tozorakimab-in-patients-with-copd-and-history-of-exacerbations-100054136",false,"NCT07566195","Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations","A Phase III, Multicentre, Open-Label, Chronic Dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)","ROMEO","Inclusion Criteria:\n\n1. Participants previously randomized in predecessor studies.\n2. Participants should be affiliated with the French Social Security system.\n3. Participants who are willing to continue using contraceptive methods as agreed to for the predecessor studies.\n4. Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n1. Clinically important pulmonary disease other than COPD.\n2. Participant meeting criteria for IP discontinuation as judged by the Investigator or the Sponsor.\n3. Current alcohol, drug or chemical abuse.\n4. Treatment with systemic corticosteroids or other immunosuppressive medication within 2 weeks prior to Visit 1 of ROMEO.\n5. Known history of:\n\n   1. Severe allergic reaction to any monoclonal and polyclonal antibody.\n   2. Allergy or reaction to any component of the IMP formulation.\n6. Receipt of blood products or immunoglobulins within 30 days prior to visit 1 of ROMEO.\n7. Receipt of live attenuated vaccines within 30 days prior to visit 1 of ROMEO.\n8. Chronic use (or expected need for chronic use during the study) of immunosuppressive medications (including, but not limited to, systemic corticosteroids), marketed or investigational biologic, or another prohibited medication.\n9. Chronic use of antibiotics if the duration of treatment is \\\u003C 3 months prior to Visit 1 of ROMEO (first IMP administration). Chronic macrolide or other antibiotic therapy is allowed provided the participant has been on a stable dose\u002Fregimen for ≥ 3 months prior to Visit 1 of ROMEO (first IMP administration) and has had at least one COPD exacerbation while on stable therapy.\n10. Use of allergen immunotherapy within 3 months of Visit 1 of ROMEO (first IMP administration), except for stable maintenance dose allergen-specific immunotherapy started 4 weeks prior to V1.\n11. Use of interferon gamma within 3 months of visit 1 of ROMEO (first IMP administration).\n12. Participation in any interventional clinical trial or receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to Visit 1 of ROMEO (first IMP administration), whichever is longer.\n13. Involvement in the planning and\u002For conduct of the study (applies to both staff employed by the Sponsor and\u002For staff at the study site).\n14. Participants who are not able to comply with the study requirements, procedures, and restrictions.","ALL","18 Years","99 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.\n\nEligible participants must have completed one of the predecessor studies.",[29,30],"Chronic Obstructive Pulmonary Disease","COPD",[32,33,29,30,34,35,36,37],"Tozorakimab","MEDI3506","Exacerbations","Safety","Biologic","Biologic Treatment","RECRUITING","2026-07-10",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":42},"2026-05-05",{"date":46,"type":23},"2028-12-29",{"name":48,"class":49},"AstraZeneca","INDUSTRY",13,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100591807","evaluation-of-ventilation-defects-downstream-of-mucus-plugs-in-patients-with-muco-obstructive-lung-disease-100591807","NCT06985225","Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease","Inclusion Criteria:\n\n* Adequate completion of informed consent process with written documentation\n* Patients 18 - 65 years old\n* • Physician diagnosis of muco-obstructive pulmonary disease, including cystic fibrosis, severe asthma, chronic obstructive pulmonary disease, or non-cystic fibrosis bronchiectasis for \\> 1 year\n* Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs.\n\nExclusion Criteria:\n\n* Respiratory tract infection within the 4 weeks prior to Visit 1\n* Body mass index (BMI) \\> 30 at Visit 1\n* One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1\n* ER visit related to pulmonary condition within the previous 4 weeks of Visit 1\n* Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.)\n* Resting O2 saturation \\\u003C90% with maximum supplemental O2 delivered by nasal canula\n* Positive urine pregnancy test\n* Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study\n* Unable or unlikely to complete study assessments in the opinion of the Investigator\n* Study intervention poses undue risk to patient in the opinion of the Investigator\n* Conditions that will prohibit MRI scanning determined by the MRI safety screening.","65 Years",{"count":59,"type":23},8,"OBSERVATIONAL","In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with muco-obstructive pulmonary disease. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.",[63,30,64,65],"Severe Asthma","Non-CF Bronchiectasis","Cystic Fibrosis (CF)",[67,68,63,30,64],"Xenon MRI","Mucus Plug","2026-06-26",{"date":71,"type":42},"2026-07-01",{"date":73,"type":42},"2025-06-01",{"date":75,"type":23},"2026-12",{"name":77,"class":78},"University of Kansas Medical Center","OTHER",1,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":79},"100554340","health-literacy-physical-and-cognitive-function-health-related-behaviors-and-quality-of-life-in-copd-100554340","NCT06497816","Health Literacy, Physical and Cognitive Function, Health-related Behaviors, and Quality of Life in COPD","An Investigation of Health Literacy, Physical and Cognitive Function, Health-related Behaviors, and Quality of Life in Chronic Obstructive Pulmonary Disease and Healthy Individuals","Inclusion criteria for the COPD group:\n\n* Being over 40 years old,\n* Diagnosed with COPD and being clinically stable,\n* Being able to cooperate with the tests to be performed,\n* Not having any cardiovascular disease, orthopedic or neurological problems that may affect the tests,\n* Being willing to participate in the study.\n\nExclusion criteria for the COPD group:\n\n* Being in an acute exacerbation period,\n* Having any cardiovascular disease, orthopedic or neurological problems that may affect the tests,\n* Not being willing to participate in the study.\n\nInclusion criteria for the control group:\n\n* Being willing to participate in the study and being over 40 years old\n* Not having any known disease\n\nExclusion criteria for the control group:\n\n* Not being able to cooperate with the tests to be performed\n* Not being willing to participate in the study",true,"40 Years",{"count":90,"type":23},144,"Health literacy is important for controlling disease progression and living a healthy life with illness. High health literacy is associated with higher cognitive performance and lower health-related quality of life. Physical, psychological, and social impairments are seen in chronic obstructive pulmonary disease (COPD). Studies investigating the relationship between health literacy and functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living in individuals with COPD are limited. Therefore, the aim of this study was to compare individuals with COPD with healthy individuals in terms of health literacy, functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living and to investigate the relationship between health literacy and functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living in individuals with COPD.",[30,93,94],"Health Literacy","Health-Related Behavior","2026-06-24",{"date":97,"type":42},"2026-06-25",{"date":99,"type":42},"2024-06-15",{"date":101,"type":23},"2027-06-15",{"name":103,"class":78},"Hacettepe University",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":24,"phases":114,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100610040","closed-loop-oxygen-control-in-chronic-obstructive-pulmonary-disease-copd-patients-treated-with-nasal-high-flow-in-the-hospital-100610040","NCT07222410","Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital","Closed Loop Oxygen Control in COPD Patients Treated With Nasal High Flow in the Hospital","Inclusion Criteria:\n\n* Has cognitive ability to provide informed consent\n* Aged 22 years or older\n* Hospitalized with hypoxemia\u002Frespiratory distress\n* Diagnosis of COPD\n* Candidate for\u002Fcurrently prescribed nasal high flow (flow rate of at least 25 L\u002Fmin) with supplemental oxygen, as assessed by the investigator\n* Expected duration of oxygen and nasal high flow therapy \\>24 hours (not necessarily continuous)\n\nExclusion Criteria:\n\n* Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society \u002FAmerican Thoracic Society guidelines\n* Hemodynamic instability (systolic blood pressure \\\u003C90mmHg or requirement for vasopressor or inotropic support)\n* Patient receiving end of life care\n* Nasal or facial conditions precluding use of nasal high flow\n* Pregnancy or breastfeeding\n* Cognitive impairment or impaired consciousness precluding informed consent\n* Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator\n* Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included\n* The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator\n* Has already participated in this clinical trial","22 Years",{"count":113,"type":23},70,[115],"NA","The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia\u002Frespiratory distress.",[30],[30,119,120,121],"closed loop oxygen control","hypoxemia","nasal high flow","2026-06-21",{"date":124,"type":42},"2026-06-23",{"date":126,"type":42},"2026-01-07",{"date":128,"type":23},"2027-11",{"name":130,"class":49},"Fisher and Paykel Healthcare",4,{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100493691","effect-of-combined-endurance-training-on-adl-and-walking-in-copd-patients-100493691","NCT05708443","Effect of Combined Endurance Training on ADL and Walking in COPD Patients","Effect of Combined Upper and Lower Extremity Endurance Training Versus Lower Extremity Training Alone on ADL and Walking in COPD Patients","Inclusion Criteria:\n\n* GOLD class 2-3 COPD\n* Forced Expiratory Volume in the first second (FEV1) between 30% and 70% of the predicted value\n* ability to walk and climb stairs without assistance\n* stable clinical condition (pH \\> 7.35)\n\nExclusion Criteria:\n\n* chronic respiratory insufficiency on long-term oxygen therapy (LTOT)\n* severe orthopedic, neurological or cardiological comorbidities\n* cognitive impairment\n* recent exacerbation (within 15 days) requiring a change in therapy\n* presence of lung disease other than COPD\n* terminality",{"count":140,"type":23},36,[115],"Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease with related exercise intolerance and marked disability due to symptoms such as dyspnea and fatigue. Effort intolerance and exercise-induced symptoms cause marked impairment in completing activities of daily living (ADL). Pulmonary rehabilitation (PR), which has exercise as a major component, is considered a key treatment in the management of COPD since PR is effective in improving exercise tolerance, exercise-induced dyspnea and fatigue, and health-related quality of life. Rehabilitation is also effective in improving the time required to perform ADLs, reducing symptoms and disability. Studies show that rehabilitation protocols with upper limb exercises added to lower limb training are able to give additional benefits in terms of effort tolerance (endurance time at the arm ergometer and oxygen consumption) and reduction of dyspnea at iso-load.\n\nThe primary aim of this study is to evaluate whether the combined \"arm and leg\" training modality, compared to a gold standard protocol -involving only the lower limbs training- is more effective in improving ADL performance in terms of reduction of exercise time for a specific test (GLITTRE test).",[30],[145,30,146,147],"ADL","Glittre Test","exercise","2026-06-19",{"date":95,"type":42},{"date":151,"type":42},"2023-01-10",{"date":153,"type":23},"2027-06-30",{"name":155,"class":78},"Istituti Clinici Scientifici Maugeri SpA",3,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":79},"100639765","copd-flare-up-clinic-after-severe-exacerbations-100639765","NCT07629869","COPD Flare-Up Clinic After Severe Exacerbations","The Role of COPD Flare-up Clinic Service After Severe Exacerbations to Reduce Recurrent Exacerbations","FLARE-COPD","Inclusion Criteria:\n\n* Prior COPD diagnosis based on clinical and spirometry accepted criteria.\n* Acute exacerbation of COPD as the main reason for ED arrival.\n* Ability to perform in-person and telephone follow-up.\n* Agree to participate, with a signed informed consent.\n\nExclusion Criteria:\n\n* Symptomatic heart failure as the main reason for emergency department visit in the last 6 months.\n* Uncontrolled comorbidity.\n* Vulnerable Populations: To ensure ethical compliance and participant safety, the study will exclude vulnerable populations. This includes pregnant women, and any person lacking the mental or legal capacity to provide independent informed consent.","80 Years",{"count":167,"type":23},240,[115],"This prospective randomized controlled trial evaluates whether a specialized \"COPD flare-up clinic service\" improves outcomes in patients following an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Patients presenting to the emergency department with AECOPD and discharged or hospitalized will be randomized 1:1 to either structured follow-up in a dedicated flare-up clinic or standard follow-up by scheduled telephone interviews.\n\nThe researches hypothesize that structured follow-up in a specialized clinic will reduce recurrent exacerbations, optimize long-term COPD management, and improve patients' quality of life compared to standard care.",[30,171],"COPD Exacerbation (AECOPD)",[173,174,175],"COPD management","COPD flare-up","COPD exacerbation","NOT_YET_RECRUITING","2026-06-18",{"date":124,"type":42},{"date":71,"type":23},{"date":181,"type":23},"2028-12-31",{"name":183,"class":184},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":18,"minAge":193,"maxAge":165,"enrollmentInfo":194,"targetDuration":4,"studyType":24,"phases":196,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100530021","trial-evaluating-the-rate-of-pneumothorax-in-severe-emphysema-secondary-to-endoscopic-volume-reduction-with-two-stage-zephyr-valves-versus-endoscopic-volume-reduction-with-one-stage-zephyr-valves-100530021","NCT06181357","Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves","Randomized Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves","REPEAT","Inclusion Criteria:\n\nPatient able to give informed consent and participate in the study\n\n* Age ≥ 35 years old and ≤ 80 years old at the time of signing the consent\n* Emphysema (homogeneous or heterogeneous) on a recent CT scan (\\\u003C 6 months). Heterogeneous emphysema defined by a difference of at least 15% destruction (threshold 910HU) between two adjacent lobes.\n* Destruction ≥ 50% (threshold 910 HU) of the target lobe on the chest scanner\n* Smoking quit for 3 months\n* Dyspnea ≥ 2 according to the modified Medical Research Council (mMRC) questionnaire)\n* Post-bronchodilator FEV between 15 and 50% theoretical\n* Post-bronchodilator total lung capacity ≥ 100% theoretical and post-bronchodilator residual volume ≥ 175% theoretical\n* Distance traveled during the TM6M ≥ 100m\n* Member of or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Asthma considered as main diagnosis\n* Recurrent exacerbations: (\\>3 over the last year or 2 requiring hospitalization)\n* Myocardial infarction or stroke in the 6 months prior to inclusion\n* Symptoms of heart failure in the 6 months prior to inclusion\n* Chest CT abnormalities: giant bulla (occupying more than a third of the pulmonary field), paraseptal emphysema, pulmonary nodule greater than 0.8cm (not applicable pulmonary nodules known for more than a year and stable), fibrosing interstitial pneumonitis, dilated bronchi\n* Pulmonary tomoscintigraphy:\n\n  * Patients for whom the least perfused lobe is not the one with the highest emphysema destruction score\n  * Patients with homogeneous emphysema for whom the perfusion delta (difference in perfusion between the ipsilateral lung and the treated lobe) is less than 10%\n* Arterial blood gas analysis in ambient air: Hypoxemia in ambient air (PaO2 \\\u003C 45 mmHg). Hypercapnia (PaCO2 \\> 55 mmHg)\n* Echocardiography:\n\n  * Left Ventricular Ejection Function \\\u003C 45%\n  * Systolic pulmonary arterial pressure \\> 45 mmHg\n* History of pneumonectomy, lung surgery homolateral to the lobe targeted for endoscopic lung volume reduction\n* History of pneumothorax homolateral to the lobe targeted for endoscopic lung volume reduction\n* History of endoscopic volume reduction\n* Oral corticosteroid therapy \\> 20 mg\u002Fday within the 4 weeks preceding inclusion\n* Symptomatic bronchial dilatations, bronchial colonization with pseudomonas aeruginosa, multi-resistant bacteria or aspergillus origin\n* Metastatic cancer undergoing treatment or whose treatments ended less than 5 years ago\n* Pregnant or breastfeeding women\n* Nickel allergy\n* Patient under guardianship, curatorship or under judicial protection\n* Participation in another interventional clinical research\n* Any other condition which, in the opinion of the investigator, could interfere with the objective of the study or would cause the subject's participation in the study to be suboptimal, in particular (non-exhaustive list) unweaned alcoholism, substance abuse, non-compliance with usual follow-up visits)\n\nsecondary exclusion criteria:\n\n\\- Evidence of collateral ventilation measured by the Chartis system","35 Years",{"count":195,"type":23},244,[115],"Chronic obstructive pulmonary disease (COPD) affects 3.5 million people and is the third leading cause of death worldwide. Emphysema involves air retention in the lungs and is ultimately responsible for a major deterioration in the quality of life. Available drug treatments have moderate efficacy whereas surgical lung volume reduction can improve exercise capacity when offered to a very selected population but at the cost of significant morbidity and mortality.\n\nEndoscopic Lung Volume reduction with ZEPHYR® valves improves respiratory function at rest, exercise tolerance and quality of life in patients with little or no interlobar collateral ventilation.\n\nIf this technique has therefore proven its effectiveness, it is not devoid of complications and is notably responsible for pneumothorax in 27% of cases. The management of this complication is clearly codified, ranging from patient monitoring to the removal of one or more valves. It is therefore a subject of major concern for multiple reasons: high incidence, lengthening of hospital stay, increase in the overall cost of care, potential loss of benefit for the patient in the event of permanent withdrawal. valves and above all a potentially fatal event.\n\nA new strategy for implanting ZEPHYR® valves in two stages has been developed in Limoges University Hospital. This innovative algorithm has been evaluated in several non-comparative single or multicenter studies. In those studies, pneumothorax' rate secondary to lung volume reduction with endobronchial valves is rated between 4.5 and 12%. The efficacy of the treatment appears to be comparable with the data found in the trials evaluating in which the entire lobe was treated in one procedure. Moreover, despite two procedures, there does not seem to be any increased risk of occurrence of other complications. Finally, the systematic scheduling of a thoracic computed tomography between the two procedures showed that 26.6% of patients presented a reduction in volume greater than 350mL despite incomplete treatment.\n\nThese data seem promising but no direct comparison with standard one-step treatment has ever been conducted so far.",[30],[200,201,202,203,30],"Endobronchial Zephyr® valves","Endoscopic lung volume reduction","Pneumothorax","Emphysema",{"date":124,"type":42},{"date":206,"type":42},"2024-05-06",{"date":208,"type":23},"2029-06-06",{"name":210,"class":78},"University Hospital, Limoges",17,{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":24,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":79},"100560515","physiologic-effects-of-nasal-high-flow-on-exercise-tolerance-in-copd-100560515","NCT06578156","Physiologic Effects of Nasal High Flow on Exercise Tolerance in COPD","Physiologic Effects of Nasal High Flow on Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Able to consent\n* Age 18 years or older\n* Diagnosis of COPD\n* Ability to ambulate without assistance\n* Use of low-flow nasal cannula ≤ 4 L\u002Fmin or no supplemental oxygen (O2) at all\n\nExclusion Criteria:\n\n* Pregnancy\n* Being on bedrest\n* Inability to consent or cooperate with the study\n* Using of \\> 4 L\u002Fmin of supplemental O2 or requiring non-invasive ventilation during the daytime\n* Hemodynamic instability (resting heart rate \\> 130\u002Fminute, systolic blood pressure of ≤ 90 mmHg or ≥ 180 mmHg)\n* Metal implants in the thoracic regions (pacemakers, Automatic Implantable Cardioverter Defibrillator (AICD), plates, screws, rods, and disc replacements)","100 Years",{"count":221,"type":23},45,[115],"This study aims to assess whether to describe the effects of the administration of nasal high flow (NHF) at 70 liters per minute (L\u002Fmin) in a 6-Minute Walk Test (6-MWT) among Chronic Obstructive Pulmonary Disease (COPD) patients and to characterize the association between self-reported dyspnea with and without NHF at 70 L\u002Fmin following a 6-MWT.",[30],"2026-06-17",{"date":227,"type":42},"2026-06-22",{"date":229,"type":42},"2024-12-12",{"date":231,"type":23},"2027-12-31",{"name":233,"class":78},"University of Miami",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":24,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":79},"100466247","thermotherapy-against-persistent-bacterial-lung-infections-100466247","NCT05351242","THERMotherapy Against Persistent Bacterial LUNG Infections","Thermotherapy Against Persistent Bacterial LUNG Infections","THERMA-LUNG","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Competent and capable\n* FEV1\\>1,0 L\n* Have had a positive culture from sputum or BAL min. 2 times in the last 24 months for bacteria of the species: Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Staphylococcus aureus, Haemophilus influenzae, Achromobacter xylosoxidans, Klebsiella oxytoca or Klebsiella pneumoniae. In addition, min. 1 positive culture after treatment with antibiotics\n* Willing to go to a sauna (min. temperature of 85℃ for at least 7 minutes) four times weekly for six months or avoid going to a sauna for six months\n\nExclusion Criteria:\n\n* Allergy to lidocaine and\u002For midazolam\n* Contraindications to bronchoscopy\n* Previous severe laryngospasm (intubation requiring)\n* Pregnancy\u002Fbreastfeeding\n* Severe linguistic problems or inability to give informed consent\n* Severe mental illness that is not controlled with medication. NB: Patients with controlled mental illness can be included and will be asked on an equal footing as others",{"count":243,"type":23},150,[115],"The aim of this study is to determine whether an intervention with frequent thermotherapy will be able to reduce the amount of colonizing bacteria in the bronchoalveolar lavage sample and eradicate the colonizing bacteria.",[247,248,249,250,29,251],"Lung Diseases, Obstructive","Bronchiectasis","Asthma","Copd","Chronic Lung Infections","2026-06-15",{"date":225,"type":42},{"date":255,"type":23},"2026-10-01",{"date":257,"type":23},"2029-12-31",{"name":259,"class":78},"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":24,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":282},"100601259","symptoms-and-functions-in-patients-with-copd-and-chronic-bronchitis-switching-from-cig-to-ths-100601259","NCT07108166","Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS","A Randomized, Single (Operator)-Blinded, Controlled Clinical Study for Assessing Major Symptoms and Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis Who Switch From Combustible Cigarettes (CIG) to Tobacco Heating System (THS)","Inclusion Criteria:\n\n* Adult, both sexes, aged ≥ 40 years.\n* Patient has read, understood, and signed the written informed consent form (ICF), which has received IEC or IRB approval.\n* Patient with body mass index (BMI) 17.6-40.0 kg\u002Fm2 and body weight \\> 50 kg (male) or \\> 40 kg (female). Checked at V1 and V2.\n* Patient has a CIG smoking history ≥ 10 years.\n* Patient has been smoking ≥ 10 commercially available and\u002For roll-your-own CIG\u002Fday on average (no brand restriction) for at least the last year (based on self-reporting). Smoking status will be verified by Urine cotinine test (UCOT) ≥200 ng\u002FmL. Intermittent CIG smoking abstinence, with or without Smoking Cessation Treatment during these attempts, not exceeding 10 days total within the past year will be allowed. Checked at V1 and V2.\n* Patient has been advised to quit smoking, informed of smoking risks and of cessation programs as per SoC at V2, and is not willing to quit CIG use for the study duration. Checked at V1 and V2.\n* Patient agrees to be randomized into one of the two study arms. Checked at V2.\n* Patient with confirmed COPD via spirometry performed at V1 (FEV1\u002FFVC \\\u003C70%, post-bronchodilator (-BD)) and COPD severity classified by the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) as GOLD 2 or 3 (30%≤ FEV1 \\\u003C 80% predicted, -BD) with presence of chronic bronchitis (cough and mucus most of the days for \\> three months a year for the two consecutive years prior to the screening visit). Checked at V2.\n* Patient has cough frequency of ≥ 10 cough\u002Fhour during daytime from objective count sensor applied at V1, used to verify eligibility at V2. (Daytime is defined as occurring between 07:00:00 and 22:59:59, based on the local time zone of the site where the patient is assessed.)\n\nExclusion Criteria:\n\n* Patient who self-report concomitant daily use of inhaled cannabis or any type of nicotine containing products other than CIG within the last year.\n* Patient with COPD (moderate or severe) exacerbation that has not resolved according to the GOLD standard (e.g., requirement of additional therapy) or investigator's discretion. Checked at V1 and V2.\n* Patient with currently active cancer or history of any cancer within the last 5 years prior to V1, except for those with basal cell carcinoma of the skin.\n* Patient with acute worsening symptoms of chronic bronchitis or other active respiratory or systemic infections that have not resolved. Checked at V1 and V2.\n* Patient with medical condition(s) that would jeopardize his(her) safety in the context of this study (e.g., safety laboratory parameters, abnormal ECG) or with a condition that would jeopardize study results (e.g., gastroesophageal reflux disease (GERD), heart failure, severe chronic lung emphysema, active symptomatic hay fever), as per Investigator's discretion. Checked at V1 and V2.\n* Patient is legally incompetent, physically, and\u002For mentally incapable of giving consent (e.g., emergency situation, under guardianship, in a social or sanitary establishment, prisoner or involuntarily incarcerated, unable to read).\n* Patient with a history of asthma.\n* Employee of the investigational site or any other party involved in the study, or their first-degree relatives (parent, child, spouse).\n* Current or former employee of the tobacco or e-cigarette industry or their 1st-degree relatives.\n* Patient with active or history of alcohol and\u002For drug abuse within the past year.\n* Patient with positive serological tests for human immunodeficiency virus (HIV) 1\u002F2, hepatitis B or C (Hep B\u002FC).\n* Patient with any concomitant issues (e.g., medical, psychiatric, and\u002For social reason) that, as per Investigator's discretion, would place the study patient at an unacceptable risk for participation in the study.\n* Patient who participated in any trial (for investigational medicine, or other type of intervention) that may have interfered with COPD disease progression and symptoms (including cough and dyspnea) within the last three months as per investigator's discretion.\n* Patient using any systemic (injectable or oral) corticosteroids (acute or chronic treatments) or oxygen therapy in the last 2 months excluding short term use for a COPD exacerbation.\n* Patient currently being treated with angiotensin-converting enzyme (ACE) inhibitors or opioids, or those who have used ACE inhibitors within 4 weeks or opioids within 1 week prior to screening. Checked at V1 and V2.\n* Patient treated with biologic therapies for COPD (e.g., Dupilumab) in the last 6 months.\n* Female patient is pregnant, breastfeeding or lactating, or anticipating becoming pregnant withing the duration of the study. Checked at V1 and V2.\n* Female of childbearing potential who is capable of getting pregnant, defined as a female patient who does not agree to use an acceptable method of effective contraception during the entire study, a female patient that is not surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year). Checked at V1 and V2.",{"count":268,"type":23},290,[115],"The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory symptoms) and function (e.g., lung function, and six-minute walking test \\[6MWT\\]) after switching to THS compared to continuing to smoking cigarettes.",[30,272,273],"Smoking","Tobacco Use","2026-06-12",{"date":252,"type":42},{"date":277,"type":42},"2025-04-02",{"date":279,"type":23},"2026-11",{"name":281,"class":49},"Philip Morris Products S.A.",112,{"id":284,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":24,"phases":287,"briefSummary":27,"conditions":288,"keywords":289,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":295,"locationsCount":50},"100636477",{"count":286,"type":23},82,[26],[29,30],[32,33,29,30,34,35,36,37],"2026-06-09",{"date":292,"type":42},"2026-06-10",{"date":44,"type":42},{"date":46,"type":23},{"name":48,"class":49},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":24,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":79},"100643372","effects-of-laura-mitchells-and-benson-relaxation-technique-on-anxiety-sleep-quality-and-fatigue-among-copd-patients-100643372","NCT07635446","Effects of Laura Mitchell's and Benson Relaxation Technique On Anxiety, Sleep Quality and Fatigue Among COPD Patients","Inclusion Criteria:\n\n\\- Gender: Male and Female\n\n* Age: 40 to 60 years\n* Patients diagnosed with COPD\n* Willing to participate\n\nExclusion Criteria:\n\n* Patients with Exacerbations within past 4 weeks\n\n  * Cardiac Diseases (Acute MI, Congestive Heart Failure)\n  * Neuromuscular Disorder\n  * Recent lung diseases\n  * Hemodynamic instability\n  * Respiratory failure","60 Years",{"count":304,"type":23},38,[115],"Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition characterized by persistent respiratory symptoms and airflow limitation. Patients with COPD often experience not only physical symptoms like breathlessness and fatigue but also psychological issues such as anxiety and poor sleep quality, which further compromise their quality of life. Non-pharmacological interventions, especially relaxation techniques, have shown promise in improving psychological well-being and physiological outcomes in COPD patients. Among these, Laura Mitchell's relaxation technique and Benson's relaxation response have gained attention for their simplicity and effectiveness.\n\nThe primary objective of this study is to assess and compare the effects of Laura Mitchell's relaxation technique and Benson's relaxation technique on anxiety, sleep quality, and fatigue levels in patients diagnosed with moderate to severe COPD. By evaluating these parameters, the study aims to determine which method provides greater benefits in managing psychological and physical symptoms associated with COPD. The study will use a randomized experimental design. Participants will be randomly assigned into two groups: Group A will receive Laura Mitchell's relaxation training, and Group B will receive Benson's technique. Both interventions will be practiced daily for 15-20 minutes over a 6-weeks period. Baseline and post-intervention (week 6) data will be collected. Outcome measures will include anxiety (GAD-7), fatigue (FSS) and sleep quality (PSQI). Data will be analyzed using paired and independent t-tests to assess within-group and between-group differences, with significance set at p \\\u003C 0.05. The data will be analyzed using SPSS v 25.",[30],[309,310,311,312,313],"Anxiety","Benson relaxation","Fatigue","Laura Mitchell's relaxation technique","Sleep quality","2026-06-08",{"date":290,"type":42},{"date":317,"type":42},"2026-06-01",{"date":319,"type":23},"2026-08-01",{"name":321,"class":78},"Riphah International University",{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":165,"enrollmentInfo":329,"targetDuration":4,"studyType":24,"phases":331,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":340,"locationsCount":79},"100643516","phase-2-a-clinical-trial-to-evaluate-the-efficacy-and-safety-of-hrs-9821-inhalation-suspension-in-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-100643516","NCT07640451","A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n1. Age ≥ 40 years old and \\\u003C 80 years old, male or female.\n2. Meet the weight standard.\n3. Smoking history ≥ 10 pack-years.\n4. COPD has been diagnosed ≥ 1 year.\n5. 4 weeks before screening, the background treatment for COPD was stable.\n6. FEV1\u002FFVC \\\u003C 0.7, 30% ≤ FEV1 ≤ 80%.\n7. mMRC score ≥ 2.\n8. The inspection and medication can be completed as required.\n9. Non-pregnant and breastfeeding state.\n10. Able and willing to provide a written informed consent.\n\nExclusion Criteria:\n\n1. History of life-threatening COPD.\n2. Other pulmonary diseases that may affect the efficacy evaluation of this study.\n3. Concurrent diseases other than COPD that may affect lung function.\n4. History of asthma.\n5. Pulmonary heart disease requiring clinical intervention, or moderate to severe pulmonary hypertension.\n6. Malignant tumors within 5 years.\n7. Uncontrolled severe cardiovascular and cerebrovascular diseases within 1 year.\n8. Unstable diseases.\n9. Acute exacerbation of COPD within 12 weeks, hospitalization for COPD or pneumonia within 6 months.\n10. Infection in the lungs or other parts occurs within 16 weeks and requires treatment.\n11. Immunosuppression.\n12. Uncontrolled hypertension.\n13. Lung resection, surgical lung volume reduction or endoscopic treatment for COPD.\n14. Undergone major surgery or planned surgery within 14 months.\n15. Abnormal chest images have clinical significance.\n16. Tuberculosis infection requiring treatment within 16 to 12 months.\n17. Virological test result was positive.\n18. Laboratory blood tests and electrocardiograms were significantly abnormal.\n19. Requires oxygen inhalation or intermittent oxygen inhalation therapy.\n20. Hypercapnia, using or requiring long-term use of any non-invasive positive pressure ventilation device.\n21. Biological agents that may have therapeutic effects on the studied disease have been used within 12 weeks or within 5 half-lives of the drug.\n22. Vaccination, theophylline or drugs within 4 weeks.\n23. Having participated in other clinical studies within 4 weeks and used research drugs or medical devices containing active ingredients, or still within 5 half-lives of the research drug.\n24. Systemic glucocorticoids, immunosuppressants, and oral Roflumilast within 12 weeks.\n25. Undergoing or planning rehabilitation treatment for pulmonary rehabilitation.\n26. Non-selective β blockers within 1 week.\n27. Overly potent\u002Fmoderately potent drugs that inhibit or induce the liver drug-metabolizing enzyme CYP3A4 within 14 days.\n28. Allergic to the research drug or salbutamol or excipients.\n29. Has been used HRS-9821.\n30. Drug abuse and alcohol abuse within 1 year.\n31. Pregnant or lactating period or planning to be pregnant or lactating.\n32. The researchers judged that there were other unsuitable circumstances.",{"count":330,"type":23},90,[332],"PHASE2","The study is being conducted to evaluate the efficacy and safety of HRS-9821 for patients with COPD, and to explore the reasonable dosage of HRS-9821 for patients with COPD.",[30],"2026-06-05",{"date":292,"type":42},{"date":338,"type":23},"2026-06",{"date":279,"type":23},{"name":341,"class":49},"Guangdong Hengrui Pharmaceutical Co., Ltd",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":24,"phases":351,"briefSummary":352,"conditions":353,"keywords":358,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":79},"100606268","hypnosis-on-breathlessness-mastery-in-patients-with-persistent-dyspnea-100606268","NCT07173348","Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea","Effectiveness of Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea: a Randomised Controlled Trial","HYPNEA","Inclusion Criteria:\n\n* Patients aged ≥ 18 years and\n* Primary diagnosis of metastatic cancer, COPD stage at least B or E, ILD, or CHF and\n* Dyspnea stage NYHA ≥ II or mMRC ≥ 2\n\nExclusion Criteria:\n\n* Have had hypnosis treatment in the last 12 months\n* Have an estimated life expectancy of less than 6 months\n* Have participated in pulmonary rehabilitation in the last 6 months\n* Have been hospitalised in the last month (30 days)\n* Are unable to come to the hospital for 3 outpatient consultations (1 every two weeks)\n* Have a condition that would interfere with their ability to respond to the questionnaires (i.e. cognitive impairment, hearing impairment, etc.)\n* Are not eligible for a hypnosis session due to a psychiatric disorder",{"count":286,"type":23},[115],"Persistent dyspnea is a debilitating symptom, that is common and difficult to treat. This symptom is found in many different diseases including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and metastatic cancer. Dyspnea is associated with many other symptoms, including anxiety, depression, and fatigue and is responsible for a significant reduction in quality of life. To date, only opiates are recommended for the pharmacological treatment of persistent dyspnea.\n\nThe effectiveness of hypnosis is well known in the treatment of anxiety and delivered to patients suffering from chronic dyspnea for this reason. One randomised controlled study has shown that a single 20-minute mindfulness sessions could significantly reduce general symptom burden and have a significant impact on anxiety and depression in palliative care patients. Furthermore, the intervention had no negative side effects.\n\nOur aim is to evaluate the effectiveness of three hypnosis sessions on breathlessness mastery in patients with persistent dyspnea, using as a primary outcome the mastery domain of a validated tool, the Chronic Respiratory Questionnaire (CRQ).",[354,355,356,30,357],"Cancer (With or Without Metastasis)","Interstitial Lung Disease (ILD)","Chronic Heart Failure (CHF)","Dyspnea",[359,360,361,29,362,363,364],"Hypnosis","Persistant dyspnea","Cancer with metastasis","Interstitial Lung Disease","Chronic Heart Failure","Palliative Care",{"date":314,"type":42},{"date":367,"type":42},"2026-04-01",{"date":369,"type":23},"2028-04-01",{"name":371,"class":78},"University Hospital, Geneva",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":87,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":79},"100527185","study-of-inflammatory-and-physiological-profiles-of-healthy-and-diseased-lung-100527185","NCT06144476","Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung","RETAIN","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Aged 18 years or above\n* Patient: known or suspected airway disease\n* Healthy volunteer: considered to be in good health with no significant comorbidity (immune disorder, cancer etc.)\n\nExclusion Criteria:\n\n* Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.\n* Surgery within the preceding 6 weeks\n* Participants who are pregnant\n* History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection\n* Alcohol or recreational drug abuse\n* Diagnosis of immunodeficiency requiring treatment\n* Unable to provide written informed consent\n* Unable to read or write English\n* Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study",{"count":380,"type":23},230,"There are over 700,000 UK hospital admissions every year with lung disease symptoms. Two of the most common lung diseases contributing to these numbers are asthma and chronic obstructive pulmonary disease (COPD). The immunopathology of these diseases is not fully understood. Matched samples from the respiratory tract and circulation will be used to identify immune patterns throughout the respiratory system to elucidate the immunopathology of airway disease.",[30,249,383],"Airway Disease",[383,385],"Pulmonary Disease","2026-06-03",{"date":388,"type":42},"2026-06-04",{"date":390,"type":42},"2024-02-08",{"date":392,"type":23},"2029-08-31",{"name":394,"class":78},"Guy's and St Thomas' NHS Foundation Trust",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":18,"minAge":302,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":24,"phases":403,"briefSummary":404,"conditions":405,"keywords":414,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":430,"locationsCount":79},"100376320","impact-of-positive-airway-pressure-therapy-on-clinical-outcomes-in-older-veterans-with-chronic-obstructive-pulmonary-disease-and-comorbid-obstructive-sleep-apnea-overlap-syndrome-100376320","NCT04179981","Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)","Inclusion Criteria:\n\n* OSA with moderate-to-severe disease, AHI 20 per hour by in-lab polysomnography with concomitant moderate-severe COPD based on pulmonary function tests (PFTS) and with past significant history (\\>10 pack-years) of smoking\n* Male or female gender\n* Age greater than or equal to 60 years\n* Stable treatment regimen for COPD\n\nExclusion Criteria:\n\n* Current or prior treatment with PAP or oral appliance\n* Central sleep apnea defined as central apnea index \\>5 per hour and comprising 50% of AHI\n* Known primary neuromuscular diseases\n* Disorders that may impact cognitive function including:\n\n  * neurodegenerative disorders\n  * traumatic brain injury\n* untreated PTSD and\u002For history of learning disability\n* Medicines that may cause or alter sleepiness: sedative hypnotics, or stimulants as these may alter the results\n* Patient is actively suicidal due to depression, unstable mental health condition\n* Epworth sleepiness score \\>16 (severe sleepiness) or a near-miss or prior automobile accident due to sleepiness within the past 12 months\n* Narcolepsy is the primary sleep disorder, with requirement of stimulant medications\n* Employed as a commercial driver or operating heavy machinery\n* On long-term oxygen therapy prior to start of study, more than 12 hr\u002Fday\n* Patients is unable to use either a nasal or face mask (e.g., facial trauma, claustrophobia)\n* Consumption of \\>3 alcoholic beverages per day or current use of some illicit drugs, as these may contribute to cognitive deficits\n* Patients who cannot give informed consent\n* Patients receiving hospice care\n* Pregnant women due to unknown risks",{"count":402,"type":23},668,[115],"Obstructive sleep apnea (OSA) and Chronic Obstructive Pulmonary Disease (COPD) are highly prevalent chronic respiratory diseases in the Veteran population. OSA co-occurring with COPD, known as Overlap Syndrome (OVS), is a complex chronic medical condition associated with grave consequences. OVS is highly prevalent in Veterans. Veterans with OVS may be at increased risk for cognitive deficits, poor sleep quality as well as a reduced quality of life (QoL). The overall objective is to study the effects of positive airway pressure therapy on clinical outcomes in patients with OVS.",[406,407,30,408,409,410,411,412,413],"Sleep Apnea Syndrome","Obstructive Sleep Apnea","Overlap Syndrome","Quality of Life","Neurocognitive Function","Sleepiness","Elderly","Positive Airway Pressure",[415,416,417,418,419,420,421,422,423,424,425],"Apnea","Sleep Apnea Syndromes","Sleep Apnea, Obstructive","Nervous System Diseases","Respiration Disorders","Respiratory Tract Diseases","Signs and Symptoms, Respiratory","positive airway pressure","cognitive function","quality of life","sleepiness",{"date":335,"type":42},{"date":428,"type":42},"2020-12-01",{"date":231,"type":23},{"name":431,"class":432},"VA Office of Research and Development","FED",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":87,"sex":18,"minAge":439,"maxAge":4,"enrollmentInfo":440,"targetDuration":442,"studyType":60,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":4},"100643772","a-study-to-evaluate-the-diagnostic-performance-of-portable-oscillometry-across-chronic-respiratory-diseases-100643772","NCT07631507","A Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases","Inclusion Criteria:\n\n* COPD group:\n\n  * Age：≥40\n  * Suspected COPD：COPD-SQ≥16，and no evidence of airflow limitation after bronchodilators\n  * Confirmed COPD：According to the diagnostic criteria in the 2021 Revised Edition of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease and the 2026 GOLD Report, a diagnosis requires the presence of symptoms (such as dyspnea, chronic cough, or sputum production), a history of exposure to risk factors (e.g., smoking, biomass fuels, occupational exposures, or air pollution), evidence of persistent airflow limitation (post-bronchodilator FEV1\u002FFVC \\\u003C 0.70), and the exclusion of alternative diagnoses.\n  * Exclude acute exacerbation within the last month Asthma group：\n  * Age：≥3\n  * Suspected asthma：Patients with chronic respiratory symptoms but no evidence of variable airflow limitation\n  * Confirmed asthma：According to the diagnostic criteria in the 2024 Chinese Guidelines for the Prevention and Treatment of Bronchial Asthma and the 2025 GINA Report, diagnosis requires the presence of recurrent symptoms (such as wheezing, shortness of breath, chest tightness, and cough) that resolve spontaneously or with treatment; evidence of variable airflow limitation (e.g., a positive bronchodilator reversibility test, a positive bronchial provocation test, or an average daily diurnal PEF variability of \\>10% over at least 7 consecutive days); and the exclusion of alternative diagnoses.\n\nHealthy subjects:\n\n* Age ≥ 3 (See Table 1 for details)\n* No respiratory symptoms（cough, expectoration, shortness of breath, wheezing, etc）\n* No history of serious cardiopulmonary or other systemic diseases, especially no history of respiratory diseases and surgery\n* No history of respiratory infection within the past 4 weeks; non-smoker or total lifetime smoking \\\u003C 100 cigarettes\n* No history of occupational exposure to harmful gases or dust, or serious pollution of the work or living environment\n* No abnormalities on chest physical examination\n* No abnormalities were found on chest imaging (X-ray, CT) records within the past year.\n* Body mass index within the normal range (18.5\\~24.9) Confirmed Bronchiectasis Group：\n* Age ≥ 3 years\n* Clinical history consistent with bronchiectasis, confirmed by CT scan\n* No other concurrent or accompanying respiratory diseases at present Confirmed ILD Group：\n* Age ≥ 3 years\n* Fibrotic interstitial lung disease: HRCT scan shows fibrotic lung disease, defined as reticular abnormalities and traction bronchiectasis with or without honeycombing, and the disease extent \\> 10%; or lung tissue biopsy indicates fibrotic interstitial changes\n* No other concurrent or accompanying respiratory diseases at present Confirmed Upper Airway Obstruction Group：\n* Age ≥ 3 years, gender not restricted\n* History of upper airway inflammation, injury, endotracheal intubation or tracheotomy, burns, foreign body aspiration, tracheal tumor, or other conditions that can cause large airway obstruction\n* Clinical manifestations are mainly dyspnea and shortness of breath, which are significantly aggravated after activity, and sometimes symptom exacerbation is related to body position\n* Pulmonary function test shows significant limitation of inspiratory or expiratory flow in the F-V curve, presenting a characteristic plateau pattern\n* At least one of the following evidences: chest CT scan or upper airway three-dimensional reconstruction confirms upper airway stenosis; laryngoscopy or bronchoscopy reveals tracheal\u002Fbronchial wall thickening and\u002For stenosis, intratracheal nodules or neoplasms, tumor infiltration, tracheal mucosal congestion, tracheal cartilage collapse, etc\n\nExclusion Criteria:\n\n* • Contraindications for oscillometry testing and spirometry testing: Oscillometry testing: Severe and intolerable dyspnea, acute exacerbation of respiratory infection, uncontrolled epilepsy, oral or facial diseases or deformities preventing proper latching, tympanic membrane perforation, need for continuous oxygen therapy, indwelling gastric tube, tracheotomy with inability to close the tube, currently undergoing artificial ventilation and unable to temporarily stop the procedure; Spirometry testing: Recent severe cardiovascular disease, epileptic seizures, uncontrolled hypertension, aortic aneurysm, severe hyperthyroidism, heart rate \\>120 bpm, tympanic membrane perforation, other respiratory infectious diseases, etc.;\n\n  * Other respiratory diseases that affect lung function results： such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, etc.; Recent surgical history that affects lung function results, including open-chest surgery, pleural effusion surgery, etc.;\n  * Poor cooperation during basic lung function tests, failing to meet quality control requirements;\n  * Breastfeeding women;\n  * Participants deemed unlikely by the researcher to comply with research procedures and restrictions.","3 Years",{"count":441,"type":23},4000,"1 Day","This is a prospective, multicenter, observational cohort study enrolling approximately 4,000 subjects across about 50 centers, including patients with COPD (confirmed and suspected), asthma (confirmed and suspected), bronchiectasis, interstitial lung disease (ILD), upper airway obstruction (UAO), and healthy controls. Participants will undergo standardized clinical assessments, cough search, FENO, ETCO2, impulse oscillometry, spirometry, and\u002For bronchodilator test, and\u002For bronchoprovocation test, and\u002For diffusion capacity test at a single baseline visit, with no investigational intervention or treatment assignment. The primary objective is to evaluate the diagnostic performance of portable impulse oscillometry in Chronic respiratory diseases and to develop an artificial intelligence diagnostic model for COPD based on oscillometry. The study duration per subject is limited to the screening\u002Fbaseline visit, with no follow-up visits planned.",[30,445,446,248,355,447],"Asthma (Diagnosis)","Chronic Respiratory Diseases","Upper Airway Obstruction","2026-06-02",{"date":314,"type":42},{"date":451,"type":23},"2026-07-30",{"date":453,"type":23},"2027-08-30",{"name":455,"class":78},"The First Affiliated Hospital of Guangzhou Medical University",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":466,"conditions":467,"keywords":468,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":479},"100640734","prospective-dynamic-cohort-study-of-phenotypic-profiles-in-patients-with-chronic-obstructive-pulmonary-disease-100640734","NCT07627763","Prospective Dynamic Cohort Study of Phenotypic Profiles in Patients With Chronic Obstructive Pulmonary Disease","Prospective Multicenter Dynamic Cohort Study to Evaluate Phenotypic Profiles of Subjects With Chronic Obstructive Pulmonary Disease (COPD-BPCO 2 Study)","COPD-BPCO 2","Inclusion Criteria:\n\nAge 18 years or older.\n\n* Stable COPD, defined as no exacerbation requiring treatment during the previous 4 weeks.\n* Confirmed COPD diagnosis based on post-bronchodilator FEV1\u002FFVC \\\u003C 70%\n\nExclusion Criteria:\n\n* Main diagnosis of bronchiectasis, asthma, or any other significant respiratory disease.\n* Patients under legal protection.\n* Pregnant women.",{"count":465,"type":23},500,"This prospective, multicenter, real-world observational cohort study will describe phenotypic profiles, patient characteristics, and treatments in adults with stable chronic obstructive pulmonary disease (COPD). The profiles observed in the current cohort will be compared with those of patients recruited between 2005 and 2018 in the previous COPD-BPCO 1 cohort. Patients will be followed for at least 3 years as part of routine care, with no study-specific visit or treatment.",[30],[424,469,470,471,30,472],"dyspnea","pulmonary function","exacerbations","CART",{"date":388,"type":42},{"date":475,"type":42},"2026-05-01",{"date":257,"type":23},{"name":478,"class":78},"Initiatives Bronchopneumopathie Chronique Obstructive (BPCO)",7,{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":111,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":24,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":507,"locationsCount":156},"100602109","a-multi-center-study-testing-a-new-implant-for-adults-with-severe-emphysema-100602109","NCT07119229","A Multi Center Study Testing a New Implant for Adults With Severe Emphysema","A Multicenter, Prospective Trial Evaluating the Safety and Efficacy of the Implantable Artificial Bronchus (IAB) in Adults Suffering From Severe Emphysema","IAB-2","Inclusion Criteria:\n\n1. Signed Informed Consent.\n2. Diagnosis of COPD\u002Femphysema.\n3. At least 22-years of age.\n4. 18 ≤ BMI ≤ 32.\n5. 6-minute walk Distance between 100-meters and 400-meters at baseline exam.\n6. Stable disease with less than 10-mg prednisone (or equivalent) daily\n7. Non-smoking for 4-months prior to screening interview (including tobacco, vaping, marijuana, etc.).\n8. FEV1 between 15% and 50% of predicted value at baseline exam.\n9. FEV1\u002FFVC \\\u003C70%.\n10. Subject has ≥25% emphysema destruction score in each lung defined by areas of low attenuation \\\u003C-950 HU, as determined by CT core lab.\n11. Subject has homogeneous or heterogeneous emphysema, and at least one lung has a 15% difference between upper and lower lobes in emphysema destruction score (\\\u003C -950HU) as determined by CT core lab.\n12. RV \\> 175% of predicted value.\n13. mMRC score ≥ 2.\n\nExclusion Criteria:\n\n* 1\\. Currently participating in another clinical study that involves surgery, interventional or pharmaceutical treatment..\n\n  2\\. α-1 Antitrypsin deficiency 3. Women of child-bearing potential. 4. More than 2 COPD exacerbation episodes requiring hospitalization in the last year prior to screening.\n\n  5\\. Any COPD exacerbations requiring hospitalization within 6-weeks of planned intervention.\n\n  6\\. Two or more instances of pneumonia episodes requiring hospitalization in the last year prior to screening.\n\n  7\\. Clinically significant mucus production or chronic bronchitis. 8. Myocardial Infarction or unstable \u002F uncontrolled congestive heart failure within 6-months of screening.\n\n  9\\. Prior lung transplant, LVRS, bullectomy, lobectomy or endoscopic lung volume reduction (ELVR).\n\n  10\\. Clinically significant bronchiectasis. 11. Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7-days.\n\n  12\\. Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure \\>45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram (completed within the last 3-months prior to screening visit). Note: the echocardiogram is not a required screening procedure.\n\n  13\\. Suspected malignant pulmonary nodule or other lung cancer. 14. HRCT collected per CT scanning protocol within the last 6-months of screening date and evaluated by clinical site personnel using 3D segmentation software shows:\n  1. Large bullae encompassing greater than 30% of either lung\n  2. Insufficient landmarks to evaluate the CT study using the software as it is intended\n  3. All lobes are less than 25% parenchyma diseased (\\\u003C -950 HU) 15. Any cardiac comorbidity which the PI believes would compromise the safety of the patient after an IAB implant.\n\n     16\\. TLC \\\u003C 100% predicted at screening. 17. DLCO \\\u003C 15% or \\> 50% of predicted value at screening. 18. PaCO2 \\> 50 mm Hg at screening. 19. PaO2 \\\u003C 45 mm Hg in room air at screening. 20. Plasma cotinine level \\> 13.7 ng\u002Fml or carboxyhemoglobin (arterial or ear lobe capillary) \\>2.5% at screening.\n\n     21\\. Current diagnosis of substance abuse disorder. 22. Current diagnosis of any of the following: Major Depressive Disorder (MDD), Schizoaffective Disorder, Schizophrenia, Borderline Personality Disorder, Bipolar Disorder.\n\n     23\\. Any other conditions, which, in the opinion of the Investigator, would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study.",{"count":22,"type":23},[115],"A study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD\u002Femphysema works, and how safe it is.",[492,203,30],"Emphysema or COPD",[494,495,496,497,498,499,500,501,502],"IAB","Stent","Emphysema treatment","emphysema study","COPD treatment","COPD study","EBV alternative","Lung volume reduction","Lung hyperinflation treatment",{"date":386,"type":42},{"date":505,"type":42},"2026-03-25",{"date":128,"type":23},{"name":508,"class":49},"Pulmair Medical, Inc.",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":18,"minAge":111,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":24,"phases":519,"briefSummary":520,"conditions":521,"keywords":522,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":535},"100599580","a-trial-of-the-implantable-artificial-bronchus-50-flex-in-patients-with-severe-emphysema-100599580","NCT07086339","A Trial of the Implantable Artificial Bronchus 50 Flex in Patients With Severe Emphysema","A Two Center Trial of the Implantable Artificial Bronchus 50 Flex (IAB 50 Flex) in Patients With Severe Emphysema","IAB-3","Inclusion Criteria:\n\n1. Signed Informed Consent\n2. Diagnosis of COPD\u002Femphysema\n3. At least 22-years of age\n4. 18 ≤ BMI ≤ 32\n5. 6-minute walk Distance of between 100 - and 400 meters\n6. Stable disease with less than 10-mg prednisone (or equivalent) daily\n7. Non-smoking for 4-months prior to screening interview (this includes tobacco, vaping, marijuana, etc.).\n8. FEV1 between 15% and 45% of predicted value at baseline exam\n9. FEV1\u002FFVC \\\u003C70%\n10. Subject has ≥25% emphysema destruction score in each lung defined by areas of low attenuation less than -950 HU, as determined by CT core lab.\n11. Subject has homogeneous or heterogeneous emphysema, and at least one lung has a 15% difference between upper and lower lobes in emphysema destruction score less than -950 HU, as determined by CT core lab.\n12. RV \\> 175% of predicted value.\n13. mMRC score ≥ 2\n\nExclusion Criteria:\n\n1. Currently participating in another clinical study that involves surgery, interventional or pharmaceutical treatment\n2. α-1 Antitrypsin deficiency\n3. Women of child-bearing potential\n4. More than 2 COPD exacerbation episodes requiring hospitalization in the last year prior to screening\n5. Any COPD exacerbations requiring hospitalization within 6-weeks of planned intervention\n6. Two or more instances of pneumonia episodes requiring hospitalization in the last year prior to screening\n7. Clinically significant mucus production or chronic bronchitis\n8. Myocardial Infarction or unstable \u002F uncontrolled congestive heart failure within 6-months of screening\n9. Prior lung transplant, LVRS, bullectomy, lobectomy or endoscopic lung volume reduction (ELVR)\n10. Clinically significant bronchiectasis\n11. Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7-days\n12. Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure \\>45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram\n13. Suspected malignant pulmonary nodule or other lung cancer\n14. HRCT collected per CT scanning protocol within the last 6 months of screening date and evaluated by clinical site personnel using 3D segmentation software shows:\n\n    * Large bullae encompassing greater than 30% of either lung\n    * Insufficient landmarks to evaluate the CT study using the software as it is intended\n    * All lobes are less than 25% parenchyma diseased (\\\u003C -950 HU).\n15. Any cardiac comorbidity which the PI believes would compromise the safety of the patient after an IAB implant\n16. TLC \\\u003C 100% predicted at screening\n17. DLCO \\\u003C 15% or \\> 50% of predicted value at screening\n18. PaCO2 \\> 50 mm Hg at screening\n19. PaO2 \\\u003C 45 mm Hg in room air at screening\n20. Plasma cotinine level \\> 13.7 ng\u002Fml or carboxyhemoglobin (arterial or ear lobe capillary) \\>2.5% at screening.\n21. Current diagnosis of substance abuse disorder.\n22. Current diagnosis of any of the following: Major Depressive Disorder (MDD), Schizoaffective Disorder, Schizophrenia, Borderline Personality Disorder, Bipolar Disorder\n23. Any other conditions, which, in the opinion of the Investigator, would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study.",{"count":518,"type":23},20,[115],"A Study at Two Hospitals Testing the Safety and Effectiveness of the IAB 50 Flex, a New Implant for Adults with Severe COPD or Emphysema",[30,203],[494,523,203,30,524,525,526,498,496,527,528],"Pulmair Medical","Lung Volume Reduction","Interventional Pulmonology","Pulmonology","lung conditions","Lung disease",{"date":386,"type":42},{"date":531,"type":42},"2026-02-04",{"date":533,"type":23},"2027-12",{"name":508,"class":49},2,{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":18,"minAge":543,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":554},"100571791","a-translational-study-for-prediction-of-biomarkers-and-identification-of-phenotype-and-endotype-of-copd-and-pre-copd-outcomes-in-chinese-population-100571791","NCT06724848","A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population","A Translational Study in Patients With COPD and Pre-COPD to Describe Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population","Inclusion Criteria:\n\n* Capable of giving signed ICF\n* Able to perform acceptable lung function testing for FEV1 according to American Thoracic Society and European Respiratory Society 2019 acceptability criteria.\n* Able and willing to comply with the requirements of the protocol including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at center.\n* Participants will be allowed to enroll into other non-intervention studies while taking part in this study.\n\nExclusion Criteria:\n\n* The participant has a history of alcohol or drug abuse within the past year, which, in the opinion of the responsible physician, contra-indicates their participation.\n* The participant has an altered mental status at the time of informed consent.\n* Clinically significant abnormal laboratory values available vital signs, ECG, or laboratory testing at the screening assessment that, which in the opinion of the investigator, could interfere with the objectives of the study or safety of the participant. -Current diagnosis of asthma.\n* Clinically important pulmonary disease.\n* COPD exacerbation, within 2 weeks prior to enrollment or during screening period.\n* History of partial or total lung resection (single lobe or segmentectomy is acceptable). Surgical or endoscopic (eg, valves) lung volume reduction within the 6 months prior to enrollment. Expected need for lung volume reduction surgery during the study.\n* Unstable disorders.\n* Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrollment. Suspected malignancy or undefined neoplasms.\n* Terminal disease and\u002For organ failure or participants otherwise considered not appropriate for the study participation.\n* Participants receipt marketed or investigational biologics biologics within 3 months or 5 half-lives prior to visit 1, whichever is longer.\n* Female participants who are pregnant.","30 Years",{"count":545,"type":23},850,"This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory\u002Fimmunological mechanisms on pre-COPD or PRISm, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants for 1-year period.",[30],{"date":448,"type":42},{"date":550,"type":42},"2024-06-05",{"date":552,"type":23},"2027-10-21",{"name":48,"class":49},14,{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":87,"sex":18,"minAge":88,"maxAge":562,"enrollmentInfo":563,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":156},"100417986","lung-macrophage-populations-and-functions-in-chronic-obstructive-pulmonary-disease-copd-susceptible-smokers-100417986","NCT04722835","Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers","Pre-COPD Pilot","Inclusion Criteria:\n\n* Ages between 40 to 75 years old.\n* History of at least 20 pack-years of smoking.\n* No diagnosis of COPD or asthma.\n* No spirometric evidence of airflow obstruction as determined by FEV1\u002FFVC ratio ≥0.7.\n* FEV1 and FVC \\>lower limit of normal.\n* Less than 1 pack-year history of tobacco smoking and no tobacco use within the past 12 months.\n* Subjects will be divided into two groups by their RV\u002FTLC:\n\nNormal RV\u002FTLC Group:\n\n• Plethysmographic RV\u002FTLC equal or less than lower limit of normal.\n\nAbnormal RV\u002FTLC Group:\n\n• Plethysmographic RV\u002FTLC higher than lower limit of normal.\n\nExclusion Criteria:\n\n* Any history of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 times IV drug usage. C- longer than 1 year usage.\n* Marijuana use \\>400 joints in lifetime or any within past 6 months.\n* Inability to walk briskly, run on treadmill, or pedal on ergometer to perform the study-required exercise level.\n* Pregnant\u002Fbreast feeding.\n* Serious and active heart conditions- defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy.\n* Liver cirrhosis.\n* History of chronic active Hepatitis B or C.","75 Years",{"count":564,"type":23},40,"Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.",[250,272,273],{"date":388,"type":42},{"date":569,"type":42},"2021-03-01",{"date":571,"type":23},"2030-12-31",{"name":573,"class":78},"University of California, San Francisco",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":30,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":581,"enrollmentInfo":582,"targetDuration":584,"studyType":60,"phases":4,"briefSummary":585,"conditions":586,"keywords":588,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":79},"100599679","copd-assessment-test-score-and-perioperative-risk-in-copd-100599679","NCT07087626","COPD Assessment Test Score and Perioperative Risk in COPD","Prediction of Perioperative Complication Risk Using Chronic Obstructive Pulmonary Disease Assessment Test Score in Chronic Obstructive Pulmonary Disease Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n* Patients aged between 40 and 70 years\n* Diagnosed with stable-stage Chronic Obstructive Pulmonary Disease (COPD) according to GOLD criteria\n* Scheduled for elective surgical intervention\n* Classified as ASA Physical Status II or III according to the American Society of Anesthesiologists (ASA)\n* Planned for postoperative follow-up and eligible for at least 72 hours of observation\n* Undergoing surgery with an expected duration of at least 150 minutes\n* Willing to participate voluntarily in the study\n\nExclusion Criteria:\n\n* Patients younger than 40 years or older than 70 years\n* History of COPD exacerbation within the past 4 weeks\n* Presence of severe cardiac failure (EF \\\u003C30%), end-stage renal disease, or active malignancy\n* Neurological disorders or cognitive impairments\n* Requirement for invasive mechanical ventilation in the preoperative period\n* Altered consciousness or any condition preventing completion of forms before anesthesia\n* Undergoing surgery with an expected duration longer than 150 minutes\n* Unwillingness to participate in the study voluntarily","70 Years",{"count":583,"type":23},120,"3 Days","The goal of this observational cohort study is to evaluate whether the COPD Assessment Test (CAT) score can predict the risk of perioperative respiratory complications in patients aged 40 to 70 years with diagnosed Chronic Obstructive Pulmonary Disease (COPD), undergoing elective surgical procedures lasting no longer than 150 minutes.\n\nThe main questions it aims to answer are:\n\n* Is there a statistically significant association between preoperative CAT scores and the incidence of intraoperative and early postoperative respiratory complications in COPD patients?\n* Can the CAT score be effectively used as a preoperative risk stratification tool to guide anesthetic and surgical decision-making?\n\nResearchers will compare two patient groups based on CAT scores: those with CAT \\\u003C10 and those with CAT ≥10 to determine whether higher CAT scores are associated with an increased incidence of perioperative respiratory complications.\n\nParticipants will:\n\n* Complete the CAT questionnaire during the preoperative evaluation\n* Undergo elective surgery with an expected duration of ≤150 minutes\n* Be monitored intraoperatively for bronchospasm, oxygen desaturation, and ventilation difficulty\n* Be monitored postoperatively (within the first 72 hours) for hypoxemia, reintubation, bronchospasm episodes, postoperative pneumonia, intensive care unit (ICU) admission, and length of hospital stay\n* Have perioperative clinical data collected and analyzed for comparative outcomes between CAT score subgroups",[30,587],"Preoperative Risk Assessment",[589,30,590,587],"COPD Assessment Test","Postoperative Respiratory Complications","2026-05-28",{"date":317,"type":42},{"date":594,"type":42},"2025-08-15",{"date":596,"type":23},"2027-02-01",{"name":598,"class":78},"Erzurum City Hospital",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":18,"minAge":193,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":24,"phases":609,"briefSummary":610,"conditions":611,"keywords":614,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":627},"100609326","effect-of-imt-in-patients-after-acute-exacerbations-of-copd-100609326","NCT07213128","Effect of IMT in Patients After Acute Exacerbations of COPD","The Effect of Home-based Inspiratory Muscle Training Compared to Usual Care on Readmission Rate in Patients After a Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Randomised, Multicentre, Parallel Group Clinical Trial: IN-SPIRED Trial","IN-SPIRED","Inclusion Criteria:\n\n* Patients admitted to the hospital ≥3 days for AECOPD\n* Read and speak French, Dutch or English\n* Age ≥ 35 years\n* Able to provide informed consent\n* Possessing a smartphone, compatible with the tele-monitoring app and able to perform video meetings.\n\nExclusion Criteria:\n\n* Patients already performing IMT at time of inclusion\n* Patients with estimated \\\u003C90 days life expectancy\n* Non-COPD pulmonary disease as primary diagnosis\n* Active malignancy\n* Inability to perform IMT or response to questionnaires (e.g., neurological\u002Fcognitive impairment)\n* Acute instable cardiac arrythmia or ischemia\n* Acute pneumothorax\n* Planned lung volume reduction procedure \\\u003C180days\n* Waitlisted for lung transplantation\n* Patients admitted to an in-hospital rehabilitation ward\n* Patients included in other interventional trial related to COPD that would interfere with our trial outcomes.",{"count":608,"type":23},358,[115],"The goal of this clinical trial is to test whether home-based inspiratory muscle training can reduce hospital readmissions and death in patients recovering from a severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD).\n\nThe main questions this study aims to answer are:\n\nDoes adding home-based inspiratory muscle training to usual care lower the risk of all-cause hospital readmission or death within 180 days after discharge? Does inspiratory muscle training improve respiratory muscle strength, symptoms of dyspnea, quality of life, and functional capacity compared to usual care?\n\nResearchers will compare patients randomized to:\n\nIntervention group: Home-based inspiratory muscle training plus usual care Control group: Usual care only\n\nto see if inspiratory muscle training leads to fewer readmissions and deaths, and better patient-reported and physiological outcomes.\n\nParticipants will:\n\nBe hospitalized for ≥3 days due to AECOPD, age ≥35 years, able to consent, and own a compatible smartphone.\n\nIn the intervention group, receives usual care and additionally inspiratory muscle training:\n\nInspiratory muscle training twice daily for 90 days, then once daily up to day 180, with remote telemonitoring via a smartphone app and online supervised sessions.\n\nThe control group will continue with usual care (pharmacological treatment, smoking cessation advice, vaccinations, and referral to pulmonary rehabilitation if available).\n\nFollow-up assessments will include hospital readmissions, survival, and quality of life questionnaires up to 12 months after discharge.",[612,30,613],"Chronic Obstructive Pulmonary Diseases","Symptom Exacerbation",[615,616,617,618],"Inspiratory muscle training","Respiratory muscle training","acute exacerbation","chronic obstructive pulmonary disease","2026-05-27",{"date":591,"type":42},{"date":622,"type":42},"2026-01-06",{"date":624,"type":23},"2029-02",{"name":626,"class":78},"KU Leuven",12,{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":636,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":638,"conditions":639,"keywords":640,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":627},"100611822","assess-accuracy-of-primary-care-asthma-and-copd-diagnosis-using-oscillometry-and-feno-vs-specialist-diagnosis-100611822","NCT07245576","Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis","A Study to Evaluate the Accuracy of Primary Care Diagnosis Using Oscillometry and Fractional Exhaled Nitric Oxide for Asthma and COPD Versus Specialist Diagnosis in Patients With Suspected Asthma or COPD","Care4All","Inclusion Criteria:\n\nPatients are eligible to be included in the study if all the following criteria apply and after providing written informed consent:\n\nSuspected asthma (asthma group)\n\n1. Patients ≥ 18 years old or with legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the ICF.\n2. Patients presenting with symptoms of wheezing, cough, chest tightness, shortness of breath, but without a clinically confirmed diagnosis of asthma.\n\nSuspected COPD (COPD group)\n\n1. Patients ≥ 40 years old at the time of signing the ICF.\n2. Patients presenting with symptoms of dyspnea, chronic cough or sputum production, but without a clinically confirmed diagnosis of COPD.\n\nExclusion Criteria:\n\nPatients are excluded from the study if any of the following criteria apply:\n\n1. Prior diagnosis of COPD or asthma.\n2. Use of ICS in the last 6 months or use of oral corticosteroids in the last 3 months.\n3. Any diseases that influence lung function result such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, and interstitial lung disease.\n4. Any history of recent surgery that affects lung function results, including but not limited to thoracotomy surgery, pneumothorax surgery, and thoracic drainage.\n5. Contraindication to spirometry or oscillometry test, or allergy to bronchodilator.\n6. Currently pregnant or breast-feeding women.\n7. If the investigator judges that the patient is unlikely to comply with study procedures, restrictions, and requirements.",{"count":637,"type":23},600,"Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry. While spirometry is a foundational tool, its diagnostic accuracy is often limited by the patient's ability to perform forceful breathing maneuvers, as well as technical and reproducibility challenges, and the need for proper equipment and training. These constraints can compromise effective diagnosis of asthma and COPD in primary care settings. Prompt and accurate diagnosis by primary care physicians is essential for better patient outcomes. Although variable airflow limitation often measured as a change in FEV1 after bronchodilator is a hallmark of asthma, inconsistencies in test quality and reversibility criteria create challenges in distinguishing asthma from COPD. These complexities highlight the need for alternative diagnostic tools beyond traditional spirometry.\n\nThis observational study is designed to evaluate the diagnostic accuracy and technical feasibility of using oscillometry and FeNO testing in primary care for suspected asthma and COPD, compared to conventional specialist-based diagnostics. The study will be conducted across 6 countries in the MEA, Asia, and Latin America, with two hospital sites per country. Primary care physicians will be trained in oscillometry and FeNO testing using standardized protocols and tools such as the Ambulatory Lung Diagnosis System following GINA and GOLD guidelines. Eligible patients will provide consent, complete a history and symptom questionnaire, and undergo primary care-based assessment for a provisional diagnosis. If specialist assessment cannot occur the same day, it will be done within three days. No follow-up visits are planned. Study outcomes will inform the feasibility and accuracy of integrating these methods into routine care, aiming to improve the early and reliable diagnosis of asthma and COPD.",[249,30],[249,30,641,642,643,644],"Oscillometry","spirometry","Fractional Exhaled Nitric Oxide Test - FeNO","Chronic Obstructive Pulmonary Disease - COPD","2026-05-26",{"date":619,"type":42},{"date":648,"type":42},"2025-12-26",{"date":650,"type":23},"2027-04-30",{"name":48,"class":49}]